Over 9 million satisfied customers in USA Patented and Certified Product specification Instructions for use We offer a 180-day money-back guarantee
We screen for safety before you ever pay
Meanwhile, according to a 2026 study, patients in the dataset who took Wegovy were 4.74 times more likely to develop ION (Ischemic optic neuropathy) than those who took another brand of GLP-1 drugs
Rather than trial-and-error dosing, your provider can choose the right medication (semaglutide injection, oral semaglutide, or tirzepatide) and anticipate your likely response pattern based on your peptide pathways
Most use validated formulas like Mifflin-St Jeor, which are widely considered dependable estimates for the general population
Many of these categories have strong emotional or habitual relevance and with the right product reformulations focused on flavor balance, nutritional content, portion control and better textures, there is tremendous opportunity to reinvigorate these categories for the GLP-1 consumer. According to a 2024 KFF Health Tracking Poll cited in the IFF report, 12% of US adults have been on a GLP-1 medication at least once in their lives, while 6% of US adults are currently on a GLP-1 drug
